NCT04773717

Brief Summary

The purpose of this study is to evaluate the effect of high-dose ascorbic acid on microcirculation in sepsis.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable sepsis

Timeline
Completed

Started Jan 2019

Typical duration for not_applicable sepsis

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2019

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 31, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 31, 2021

Completed
21 days until next milestone

First Submitted

Initial submission to the registry

February 21, 2021

Completed
5 days until next milestone

First Posted

Study publicly available on registry

February 26, 2021

Completed
Last Updated

March 3, 2021

Status Verified

February 1, 2021

Enrollment Period

2.1 years

First QC Date

February 21, 2021

Last Update Submit

February 28, 2021

Conditions

Keywords

SepsisMicrocirculationAscorbic acid

Outcome Measures

Primary Outcomes (2)

  • Microvascular flow index (MFI)

    Changes in MFI

    Baseline, after 0.5, 6, 12, 24, 48, 72 and 96 hours

  • Proportion of perfused small vessels (PPV)

    Changes in PPV

    Baseline, after 0.5, 6, 12, 24, 48, 72 and 96 hours

Study Arms (2)

Ascorbic acid

EXPERIMENTAL

Patients received a high dose of intravenous ascorbic acid in four equal parts daily for 96 hours. Images of sublingual microcirculation were obtained at a baseline, after 0.5, 6, 12, 24, 48, 72, and 96 hours.

Drug: Ascorbic acid

Placebo

PLACEBO COMPARATOR

Patients received placebo solution matching ascorbic acid solution as four equal parts daily for 96 hours. Images of sublingual microcirculation were obtained at a baseline, after 0.5, 6, 12, 24, 48, 72, and 96 hours.

Drug: Placebo

Interventions

200mg/kg/24h in four equal parts

Ascorbic acid

The same regimen as ascorbic acid.

Placebo

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with sepsis or septic shock within the first 24 hours after ICU admission.

You may not qualify if:

  • Age \< 18 years,
  • Pregnancy,
  • Advanced malignancy,
  • History of kidney stone, glucose-6-phosphate deficiency, hemochromatosis, or solid organ transplantation,
  • Oral mucosal inflammation or injury or technical difficulties in obtaining sublingual images.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Lithuanian University of Health Sciences Hospital Kaunas Clinics

Kaunas, Lithuania

Location

Related Publications (1)

  • Belousoviene E, Pranskuniene Z, Vaitkaitiene E, Pilvinis V, Pranskunas A. Effect of high-dose intravenous ascorbic acid on microcirculation and endothelial glycocalyx during sepsis and septic shock: a double-blind, randomized, placebo-controlled study. BMC Anesthesiol. 2023 Sep 12;23(1):309. doi: 10.1186/s12871-023-02265-z.

MeSH Terms

Conditions

SepsisShock, Septic

Interventions

Ascorbic Acid

Condition Hierarchy (Ancestors)

InfectionsSystemic Inflammatory Response SyndromeInflammationPathologic ProcessesPathological Conditions, Signs and SymptomsShock

Intervention Hierarchy (Ancestors)

Sugar AcidsAcids, AcyclicCarboxylic AcidsOrganic ChemicalsHydroxy AcidsCarbohydrates

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

February 21, 2021

First Posted

February 26, 2021

Study Start

January 1, 2019

Primary Completion

January 31, 2021

Study Completion

January 31, 2021

Last Updated

March 3, 2021

Record last verified: 2021-02

Locations